We Are Rebranding Suboptimal Care as Real-World Practice
When the press release for KEYNOTE-091 came out in mid-January, it was only logical to compare the outcomes for patients with those of the 2021 IMpower010 trial — both trials were looking at adjuvant immunotherapy following surgery for early-stage non–small cell lung cancer (NSCLC).